Product Details
| Product Name:
Luxdegalutamide |
CAS No.:
2750830-09-0 |
| Purity:
99.95% |
Supply Ability:
10g |
| Release date:
2026/05/28 |
Product Introduction
Bioactivity
| Name | Luxdegalutamide |
| Description | Luxdegalutamide (ARV-766) is a PROTAC and a protein degrader targeting the androgen receptor, capable of effectively degrading wild-type and drug-resistant mutants including L702H, H875Y, and T878A. With oral bioactivity and cell permeability, this compound is used in castration-resistant prostate cancer research and exhibits significant antitumor activity. |
| In vitro | Methods: Human primary hepatocytes were treated with various concentrations of Luxdegalutamide (0.03–30 μM) for 48 hours, and mRNA expression levels of CYP1A2, 2B6, 2C9, 2C8, and CYP3A4 were detected.
Results: Luxdegalutamide induced CYP3A4 and CYP2C8 mRNA expression, but did not induce CYP1A2, 2B6, or 2C9 mRNA expression, indicating that this drug essentially does not cause cytochrome P450 (CYP) and transporter-mediated drug-drug interactions (DDI). [1] |
| In vivo | Luxdegalutamide (ARV-766) significantly and dose-dependently inhibits tumor growth in mouse LNCaP and VCaP xenograft models.[2] |
| Storage | Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (309.43 mM)
|
| Keywords | PROTAC | Luxdegalutamide | ARV766 | ARV 766 | AndrogenReceptor | Androgen Receptor |
| Inhibitors Related | Dehydroisoandrosterone 3-acetate | 2-Ethylhexyl trans-4-methoxycinnamate | S-23 | Enzalutamide | Octinoxate | Testosterone propionate | Allura Red AC | Sunset Yellow FCF | Ostarine | Vepdegestrant | 2-sec-Butylphenol | Flutamide |
| Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Hubei Chuchang Biotech Co., Ltd.
|
2025-03-16 |
United States